PRIMARY MYELOFIBROSIS
Clinical trials for PRIMARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for PRIMARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a daily pill shrink the spleen in myelofibrosis?
Disease control TerminatedThis phase 3 trial is testing an experimental oral drug, SAR302503, in people with a rare bone marrow disorder called myelofibrosis who have an enlarged spleen. Participants are randomly assigned to receive one of two doses of the drug or a placebo. The main goal is to see if the…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for myelofibrosis patients who stop responding to standard therapy
Disease control TerminatedThis phase 2 trial tests an experimental drug called SAR302503 in people with myelofibrosis who have already been treated with ruxolitinib. The main goal is to see if the drug can shrink the spleen by at least 35% after six months of daily oral capsules. The study also tracks whe…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for myelofibrosis patients who failed standard therapy?
Disease control TerminatedThis study tested a drug called selinexor in 17 people with a rare bone marrow cancer (myelofibrosis) that did not respond to or could not tolerate standard JAK inhibitor treatments. The main goal was to see if the drug could shrink an enlarged spleen by at least 35%. The trial w…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental drug P1101 tested for rare bone marrow disease
Disease control TerminatedThis phase 2 trial tested a drug called P1101 (a type of interferon) in 11 people with early myelofibrosis, a rare bone marrow disorder. The goal was to see if the drug could shrink the spleen, improve symptoms, or boost blood counts. The study was terminated early, so the full r…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Myelofibrosis drug combo trial ends early – what it means
Disease control TerminatedThis phase 3 trial tested whether adding parsaclisib to the standard drug ruxolitinib could better shrink the spleen and ease symptoms in people with myelofibrosis. The study enrolled 252 participants but was terminated early, so the full results are not available. The goal was t…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy aims to shrink spleen and ease symptoms in hard-to-treat myelofibrosis
Disease control TerminatedThis study tested whether adding the experimental drug parsaclisib to the standard drug ruxolitinib helps people with myelofibrosis whose spleen and symptoms haven't improved enough on ruxolitinib alone. The main goal was to see if the combination could shrink the spleen by at le…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC